

REMARKS


All of pending claims 1–5 were rejected on the grounds of obviousness type double patenting over US Patent No. 6,245,227, which is jointly owned by Advion BioSciences, Inc. and Kionix, Inc., as evidenced by assignment documents of record in the United States Patent and Trademark Office.

A Terminal Disclaimer is provided herewith from each of the joint owners of this cited patent. A Fee Transmittal is enclosed to cover the fee of \$55 for the Terminal Disclaimer.

Applicants believe this application is now in condition for allowance. They urge the Examiner to telephone their undersigned counsel in the event any remaining impediment exists with respect to immediate allowance of this application.

DATED this 23rd of September, 2004.

Respectfully submitted,



David O. Seeley, Reg. No. 30,148  
Customer No. 34013  
HOLME ROBERTS & OWEN LLP  
299 South Main Street, Suite 1800  
Salt Lake City, UT 84111  
801-521-5800